ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1695

Prolonged Exposure to Subcutaneous and Intravenous Abatacept in Patients with Rheumatoid Arthritis Does Not Affect Rates of Infection, Malignancy and Autoimmune Events: Results From Pooled Clinical Trial Data

M. C. Genovese1, M C. Hochberg2, R. B. Cohen3, M. E. Weinblatt4, J. Kaine5, Edward Keystone6, P. Nash7, I. Delaet8 and R. Alten9, 1Stanford University, Palo Alto, CA, 2Department of Medicine, University of Maryland, Baltimore, MD, 3Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 4Rheumatology & Immunology, Brigham & Women's Hospital, Boston, MA, 5Sarasota Arthritis Research Center, Sarasota, FL, 6Mount Sinai Hospital, Toronto, ON, Canada, 7University of Queensland, Brisbane, Australia, 8Bristol-Myers Squibb, Princeton, NJ and Bristol-Myers Squibb, Hopewell, VA, 9Schlosspark-Klinik, University Medicine, Berlin, Germany

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Abatacept, clinical trials and rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Session Information

Title: Rheumatoid Arthritis Treatment - Small Molecules, Biologics and Gene Therapy: Safety II

Session Type: Abstract Submissions (ACR)

Background/Purpose: Disease-modifying therapies for RA have proven efficacy, but these drugs may have selective toxicities, such as malignancy, that may increase with duration of treatment. Periodic re-evaluation of incidence rates (IRs) allows assessment of any cumulative or new events over time. Using the largest pool of integrated abatacept clinical trial data to date, we investigated the long-term (LT) safety of subcutaneous (SC) and intravenous (IV) abatacept.1,2 Methods: Data were pooled from the cumulative (double-blind and open-label short-term [ST] and open-label LT extension) periods of 13 clinical studies, including one Phase II and four Phase III trials with SC abatacept,1 and two Phase II and six Phase III trials with IV abatacept.2 IRs for adverse events (AEs), serious AEs (SAEs), infection, malignancy and autoimmune AEs were calculated as events per 100 patient-years (pt-yrs) of exposure (Poisson 95% CI). IRs for the cumulative period were compared with IRs originally estimated from the pooled ST periods of the eight IV abatacept clinical studies.2 Results: A total of 6028 patients received IV or SC abatacept during the cumulative period, with abatacept exposure of 16,670.56 pt-yrs; 1167 patients received abatacept for >5 yrs. IRs of AEs, SAEs, infections or serious infections did not increase in the cumulative relative to ST periods (Table). The most frequently reported serious infections in the cumulative period were pneumonia (IR: 0.43 [0.34, 0.54]), upper respiratory tract infection (0.18 [0.12, 0.26]) and cellulitis (0.15 [0.10, 0.23]). There was no increase in IRs between the ST and cumulative periods for hospitalized, opportunistic or tuberculosis infections. The IRs of overall malignancy, combined lymphomas and lung cancers did not increase in the cumulative versus the ST periods; the most common malignancies in the cumulative period were basal cell carcinoma (IR: 0.46 [0.36, 0.58]), squamous cell carcinoma (IR: 0.15 [0.09, 0.22]), breast cancer (IR: 0.12 [0.07, 0.19]) and squamous cell carcinoma of the skin (0.08 [0.04, 0.14]). The IR of autoimmune AEs during the cumulative period was comparable to the ST period, the most common event being psoriasis (IR: 0.51 [0.40, 0.63]).

Conclusion: Based on the cumulative short-term and long-term exposure of 6028 patients to IV or SC abatacept (16,670.56 pt-yrs), the incidence rates and events reported with long-term abatacept treatment were similar to those reported in the short-term, with no increase in rate for any event with increasing exposure. These findings demonstrate that IV and SC abatacept are both well tolerated over the long-term.

  1Alten R et al. Arthritis Rheum 2011;63(10 Suppl):S150. 2Hochberg M et al. Arthritis Rheum 2010;62(10 Suppl):S164.  

 

ST period
(N=3173)

Cumulative (ST + LT) period (N=6028)

Exposure, pt-yrs

2330.82

16,670.56

AE

386.70 (372.31, 401.51)

213.95 (208.33, 219.68)

SAE

18.10 (16.37, 19.97)

13.24 (12.63, 13.88)

Death

0.51 (0.27, 0.90)

0.60 (0.49, 0.73)

Infection

98.00 (93.20, 102.99)

66.33 (64.33, 68.37)

    Hospitalized

3.33 (2.63, 4.16)

2.37 (2.14, 2.63)

Serious infection

3.68 (2.94, 4.55)

2.57 (2.32, 2.83)

Malignancy

1.55 (1.09, 2.15)

1.35 (1.18, 1.55)

Autoimmune event

2.07 (1.53, 2.75)

1.83 (1.62, 2.05)

Presented are incidence rates, calculated as events/100 pt-yrs (Poisson 95% CI), unless otherwise stated; includes events occurring up to 56 and 60 days post-last dose for Phase III and II studies, respectively; ST=Short-term; LT=Long-term

 

Disclosure:

M. C. Genovese,

Bristol-Myers Squibb,

2,

Bristol-Myers Squibb,

5;

M. C. Hochberg,

Abbott Laboratories, Astra-Zeneca, Bioiberica S.A., Eli Lilly Inc., Genentech/Roche, Merck Inc., Novartis Pharma A.G., Pfizer Inc., Stryker LLC, Xoma.,

5;

R. B. Cohen,

Bristol-Myers Squibb,

5;

M. E. Weinblatt,

Bristol-Myers Squibb,

2,

Bristol-Myers Squibb,

5;

J. Kaine,

Bristol-Myers Squibb,

5,

Bristol-Myers Squibb,

8;

E. Keystone,

Amgen, Janssen, Roche,

2,

Amgen, Janssen, Roche, UCB, Abbott, Lilly, BMS,

5;

P. Nash,

Bristol-Myers Squibb,

2,

Bristol-Myers Squibb,

5,

Bristol-Myers Squibb,

8;

I. Delaet,

Bristol-Myers Squibb,

1,

Bristol-Myers Squibb,

3;

R. Alten,

ABBOTT, BMS, GSK,NOVARTIS, PFIZER, UCB,

2.

  • Tweet
  • Email
  • Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/prolonged-exposure-to-subcutaneous-and-intravenous-abatacept-in-patients-with-rheumatoid-arthritis-does-not-affect-rates-of-infection-malignancy-and-autoimmune-events-results-from-pooled-clinical-tr/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology